Core Viewpoint - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for 10 companies, including Changchun High-tech (000661.SZ), which is seeking to list on the Hong Kong Stock Exchange. The CSRC has requested additional information regarding the company's fundraising purposes and its involvement in AI large models [1][2]. Group 1: Regulatory Requirements - The CSRC has requested Changchun High-tech to clarify the ownership structure of its controlling shareholder, Jilin Province Xinzhen Fund Partnership, and whether there are any legal restrictions on shareholding [1]. - The company must provide details on the potential impact of share pledges by its controlling shareholder on the control of the issuer, including the reasons for stock pledges and the repayment capabilities of relevant parties [1]. - The CSRC has asked for a detailed explanation of the company's business related to AI large models, including application scenarios and specific functionalities [1]. Group 2: Fundraising and Business Operations - Changchun High-tech is required to provide a detailed account of the intended use of the funds raised from the listing [2]. - The company must confirm the legality and compliance of its establishment and any changes in shareholding, focusing on significant aspects [3]. - The company needs to elaborate on its subsidiaries' business operations, including internet information services, clinical trial services, and whether they have obtained necessary qualifications and licenses [3]. Group 3: Company Overview - Changchun High-tech is an innovation-driven pharmaceutical group with a comprehensive portfolio covering therapeutic biological agents, chemical drugs, vaccines, and traditional Chinese medicine [3]. - The company is one of the few domestic pharmaceutical enterprises capable of achieving full industry chain capabilities in research and development, production, and commercialization across all major drug registration types in China [3]. - It has established a strong and diversified product portfolio in areas such as endocrine and metabolic diseases, women's health, immune and respiratory diseases, tumors, vaccines, and traditional Chinese medicine [3].

Summary of Key Points Core Viewpoint - Changchun High-tech (SZ 000661) announced a share buyback program, completing the repurchase of approximately 3.89 million shares, which is 0.95% of the total share capital, with a total transaction amount of around 400 million RMB [1]. Company Financials - As of the first half of 2025, the revenue composition of Changchun High-tech is as follows: pharmaceutical industry accounts for 92.83%, real estate for 6.81%, and service industry for 0.36% [1]. - The highest transaction price during the buyback was 112.25 RMB per share, while the lowest was 84 RMB per share [1]. - The current market capitalization of Changchun High-tech is 42.6 billion RMB [1].

Core Viewpoint - Changchun High-tech (000661) announced the approval of clinical trial applications for two products from its subsidiary, Jinsai Pharmaceutical, aimed at treating specific medical conditions [1] Group 1: Product Approvals - Jinsai Pharmaceutical's injection product GenSci140 has received approval for clinical trials, intended for the treatment of locally advanced or metastatic solid tumors [1] - The GS3-007a dry mixed suspension from Jinsai Pharmaceutical has also been approved for clinical trials, targeting growth retardation in children due to endogenous growth hormone deficiency (PGHD) [1]

Core Viewpoint - Changchun High-tech (000661.SZ) has completed a share buyback program, repurchasing a total of 3,894,517 shares, which represents 0.95% of the company's total share capital [1] Summary by Categories Share Buyback Details - The buyback was conducted through a dedicated securities account via centralized bidding [1] - The highest transaction price was 112.25 CNY per share, while the lowest was 84.00 CNY per share [1] - The total transaction amount reached 399,999,400.76 CNY, including transaction fees [1] Compliance and Strategy - The buyback aligns with relevant laws, regulations, and normative documents [1] - The actions taken are consistent with the company's established buyback plan [1]

格隆汇11月14日丨长春高新(000661.SZ)公布，截至2025年11月13日，公司股份回购期限届满。公司累 计通过回购专用证券账户，以集中竞价交易方式累计回购公司股份3,894,517股，占本公司总股本的 0.95%，其中最高成交价为112.25元/股，最低成交价为84.00元/股，合计成交金额为人民币 399,999,400.76元（含交易费用）。本次回购符合相关法律、法规和规范性文件的要求，符合公司既定 的回购方案。 ...

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of GS3-007a, a drug aimed at treating pediatric growth hormone deficiency [1] Group 1 - Changchun Jinsai Pharmaceutical has developed GS3-007a, an oral small molecule growth hormone secretagogue [1] - The drug is classified as a Class 1 chemical drug and is intended for the treatment of pediatric growth hormone deficiency (PGHD) [1] - The approval marks a significant milestone for the company in advancing its product pipeline [1]

证券代码：000661 证券简称：长春高新 公告编号：2025-147 长春高新技术产业（集团）股份有限公司 关于子公司注射用 GenSci140 境内生产药品注册临床试验申请 获得批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）子公 司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到国家药品监督 管理局核准签发的《药物临床试验批准通知书》，金赛药业注射用 GenSci140 的 境内生产药品注册临床试验申请获得批准，现将相关情况公告如下： 一、药品的基本情况 产品名称：注射用 GenSci140 申请事项：境内生产药品注册临床试验 受理号：CXSL2500763 申请人：长春金赛药业有限责任公司 审批结论：经审查，同意本品开展临床试验 适应症：晚期实体瘤 二、药品的其它情况 GenSci140 是金赛药业自主研发的一款新型靶向叶酸受体α亚型（Folate Receptor Alpha, 以下简称"FRα"）的双表位抗体药物偶联物，属治疗用生物制品 1 类药物，拟用于局部晚期或转 ...

证券代码：000661 证券简称：长春高新 公告编号：2025-148 申请事项：境内生产药品注册临床试验 受理号：CXHL2500968 申请人：长春金赛药业有限责任公司 审批结论：经审查，同意本品开展临床试验 长春高新技术产业（集团）股份有限公司 关于子公司 GS3-007a 干混悬剂境内生产药品注册临床试验申请 获得批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）控股 子公司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到国家药品 监督管理局核准签发的《药物临床试验批准通知书》，金赛药业 GS3-007a 干混 悬剂的境内生产药品注册临床试验申请获得批准，现将有关情况公告如下： 一、药品的基本情况 产品名称：GS3-007a 干混悬剂 适应症：用于生长激素缺乏症所致的儿童生长缓慢 二、药品的其它情况 GS3-007a 干混悬剂是金赛药业自主研发的口服小分子生长激素促分泌药物， 注册分类为化药 1 类，拟用于因内源性生长激素缺乏所引起的儿童生长缓慢 （PGHD）的治疗。 PG ...

Core Viewpoint - The Medical Health Index (980016) closed at 6572.66 points, down 0.65%, with a trading volume of 23.397 billion yuan and a turnover rate of 0.87% on November 14 [1] Group 1: Index Performance - Among the index constituents, 16 stocks rose while 33 stocks fell, with Ganli Pharmaceutical leading the gainers at a 2.0% increase and Yirui Technology leading the decliners at a 3.74% decrease [1] - The top ten constituents of the Medical Health Index include major companies such as WuXi AppTec, Hengrui Medicine, and Mindray Medical, with respective weights of 13.66%, 11.00%, and 7.57% [1] Group 2: Market Capitalization and Stock Prices - The total market capitalization of the top ten constituents ranges from 553.09 billion yuan for Kelun Pharmaceutical to 4603.55 billion yuan for Rihai Shenzhou, with stock prices varying from 12.25 yuan to 298.80 yuan [1] - The performance of the top ten stocks shows a mix of slight declines, with WuXi AppTec down 1.49% and Hengrui Medicine down 1.04% [1] Group 3: Capital Flow - The Medical Health Index constituents experienced a net outflow of 472 million yuan from major funds, while retail investors saw a net inflow of 388 million yuan [1] - Detailed capital flow data indicates that Ganli Pharmaceutical had a net inflow of 62.98 million yuan from major funds, despite a net outflow from retail investors [2]

Group 1: China Construction - The total new contracts signed by China Construction from January to October reached 3.61 trillion yuan, representing a year-on-year increase of 1% [1] Group 2: Changyuan Power - Changyuan Power's subsidiary received approval for the 100MW wind power project in Songzi, Hubei [2] Group 3: China Metallurgical Group - China Metallurgical Group reported a total new contract amount of 845.07 billion yuan from January to October, a decrease of 11.8% year-on-year, while overseas contracts increased by 7.3% to 71.16 billion yuan [4] Group 4: Shapuaisi - Shapuaisi received approval for clinical trials of deoxycorticosterone ketone solution, intended for use during cataract surgery [5] Group 5: Jianfeng Group - Jianfeng Group's subsidiary received approval for clinical trials of a new drug for treating advanced non-squamous non-small cell lung cancer [7] Group 6: Chongqing Steel - Chongqing Steel announced the resignation of its president Meng Wenwang due to work adjustments [8] Group 7: Tianma Technology - Tianma Technology reported an output of approximately 1732.99 tons of eel in October, with a total output of about 15218.73 tons from January to October [10] Group 8: Qingyuan Co. - Qingyuan Co.'s controlling shareholder reduced holdings of convertible bonds by 685,400 units, accounting for 13.71% of the total issuance [11] Group 9: Spring Airlines - Spring Airlines reported a passenger turnover of 506,200.49 million kilometers in October, a year-on-year increase of 20.06% [12] Group 10: China Merchants Port - China Merchants Port reported a total container volume of 17.1714 million TEUs from January to October, a year-on-year increase of 5.1% [13] Group 11: Yangdian Technology - Yangdian Technology announced a change in control following a share transfer [15] Group 12: Wanfu Biology - Wanfu Biology decided to postpone the implementation of its Knowledge City production base project [16] Group 13: Iwu Biology - Iwu Biology terminated the research project for a specific drug, which will reduce its 2025 net profit by approximately 333.79 million yuan [17] Group 14: Hainan Rubber - Hainan Rubber received an insurance payout of 22.9241 million yuan due to revenue loss from rubber price fluctuations [19] Group 15: Xinjiang Tianye - Xinjiang Tianye plans to establish a joint venture with Tianchi Energy to develop coal chemical projects [20] Group 16: China Coal Energy - China Coal Energy's executive director and president Zhao Rongzhe resigned due to reaching retirement age [22] Group 17: Huading Co. - Huading Co. received approval for a stock issuance to specific investors from the Shanghai Stock Exchange [24] Group 18: Zhongmu Co. - Zhongmu Co. decided to waive its right of first refusal for a 4.04% stake in a subsidiary [25] Group 19: Tianlong Co. - Tianlong Co. reported that its subsidiary's stock issuance was approved by the Beijing Stock Exchange [26] Group 20: Hualan Co. - Hualan Co.'s subsidiary plans to invest 20 million yuan in a biotechnology company [27] Group 21: Haichen Pharmaceutical - Haichen Pharmaceutical received a drug registration certificate for a new injection [28] Group 22: Aier Eye Hospital - Aier Eye Hospital plans to invest 300 million yuan in wealth management products [29] Group 23: Xiamen Engineering Machinery - Xiamen Engineering Machinery announced a planned share reduction by a major shareholder [30] Group 24: Guotai Group - Guotai Group successfully acquired 100% of a mining technology company for 110.1 million yuan [31] Group 25: Wanfeng Aowei - Wanfeng Aowei reached a settlement regarding an arbitration matter with a subsidiary [32] Group 26: Taihe Technology - Taihe Technology is undergoing technical upgrades for its ethylene carbonate project [33] Group 27: Renhe Pharmaceutical - Renhe Pharmaceutical's controlling shareholder plans to reduce holdings by 0.21% [34] Group 28: Changshu Bank - Changshu Bank's second-largest shareholder increased its stake to 3.98% [35] Group 29: Overseas Chinese Town A - Overseas Chinese Town A reported a 57% decrease in contract sales in October [36] Group 30: Canadian Solar - Canadian Solar's controlling shareholder expects total revenue of 1.3 to 1.5 billion USD in Q4 2025 [38] Group 31: Zhonggong Education - Zhonggong Education's controlling shareholder's shares will be auctioned due to a loan dispute [40] Group 32: Aikexibo - Aikexibo's shareholders plan to reduce their holdings by up to 3% [42] Group 33: Wanhua Chemical - Wanhua Chemical's shareholder plans to reduce holdings by up to 0.5% [44] Group 34: Jujie Microfiber - Jujie Microfiber's controlling shareholder plans to reduce holdings by up to 2% [45] Group 35: Wangsu Technology - Wangsu Technology's shareholder plans to reduce holdings by up to 1% [46] Group 36: Tianli Lithium Energy - Tianli Lithium Energy received a patent for lithium-ion battery materials [47] Group 37: Heshun Electric - Heshun Electric won a 40 million yuan project for energy storage services [49] Group 38: Changchun High-tech - Changchun High-tech's subsidiary received FDA approval for a clinical trial of a new drug [51] Group 39: Dongrui Co. - Dongrui Co. received an additional export quota for live pigs to Hong Kong [52] Group 40: Zhongwei Co. - Zhongwei Co. set the H-share issuance price at 34 HKD per share [53] Group 41: Fospower Technology - Fospower Technology plans to invest in a lithium sulfide project with partners [54]